anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a transmucous absorbefacient for a hardly absorbable drug, by using a (thio)ether compound of monosaccharides or disaccharides as an active component. CONSTITUTION:The objective transmucous absorbefacient contains an ether compound or thioether compound of monosaccharides (e.g. L-arabinose or D- mannose) or disaccharides (e.g. maltose) and a 6-18C aliphatic hydrocarbon, preferably a compound of formula I or formula II (A is O or S; R is 6-18C aliphatic hydrocarbon group). The amount of drug component in a mucous administration drug containing said absorbefacient is preferably 0.1-20wt.%, especially 0.5-5wt.%. The (thio)ether compound is e.g. n-octyl-beta-D-(thio) glucopyranoside or n-lauryl-beta-D-maltopyranoside.
<P>PROBLEM TO BE SOLVED: To provide a technique for improving the adhesiveness-maintaining property of a coating film formed on a skin in a water-in-oil emulsion type powder-containing external preparation for the skin.  <P>SOLUTION: This water-in-oil emulsion type powder-containing external preparation for the skins is characterized by containing a powder having an N-acylamino acid salt-containing coating layer in an amount of 5 to 50 mass%. The N-acylamino acid salt is preferably aluminum N-lauroyl glutamate and/or aluminum N-stearoyl glutamate. It is preferable to contain an organic-modified clay mineral as an emulsifying component. In addition, it is preferable that an acryl-silicone-based graft copolymer and 12-hydroxystearic acid are contained.  <P>COPYRIGHT: (C)2009,JPO&INPIT
1,137,170. Nucleic acids; enzymes. UNIVERSITY OF ILLINOIS FOUNDATION. 6 Sept., 1966 [29 Sept., 1965; 18 March, 1966; 23 June, 1966], No. 39867/66. Heading C3H. Biologically active intact nucleic acid is synthesized in vitro by providing an activated system capable of synthesizing biologically active nucleic acid for prolonged or extensive periods, which system includes biologically active intact nucleic acid, the specific replicase for said nucleic acid which is free of detectable destructive contaminants, and nucleotide base component or components, and recovering the synthesized nucleic acid from said system. The replicase may be obtained from a bacterium (e.g. E. coli) infected with the appropriate nucleic acid or with a virus containing the nucleic acid.
Predicting fluid responsiveness is important in the operating room in order to avoid unnecessary fluid administration. Over the last 15 years, a number of dynamic tests have been developed which are based on the principle of inducing short-term changes in cardiac preload, using heart-lung interactions, the passive leg raise or by the infusion of small volumes of fluid, and to observe the resulting effect on cardiac output or stroke volume. Pulse pressure and stroke volume variations were first developed, but they are reliable only under strict conditions. The variations in vena caval diameters share many limitations of pulse pressure variations. The passive leg-raising test is now supported by solid evidence and is more frequently used but not practical in the operating room. More recently, the end-expiratory occlusion test has also been described, which is easily performed in ventilated patients. Unlike the traditional fluid challenge, these dynamic tests do not lead to fluid overload. The dynamic tests require the insertion of an arterial catheter linked to an advanced cardiac output monitoring device which is costly and not applicable in lower risk patients without an arterial line.

In the operating room, it is recommended to use alveolar recruitment maneuvers, consisting in the transient administration of higher pressure levels, allowing to re-ventilate certain pulmonary territories by re-expanding alveoli that would have collapsed under mechanical ventilation. In daily practice, it is generally accepted that a patient presenting a significant fall in stroke volume or mean arterial pressure during an alveolar recruitment maneuver is preload dependent, but the scientific evidence in the literature remains insufficient to date. A previous study has also demonstrated the ability to predict fluid responsiveness via analysis of central venous pressure during a recruitment maneuver. By extrapolation, we would like to evaluate the capacity of peripheral venous pressure to predict this fluid responsiveness.
The aim of this study is to obtain finer details of tissues surrounding a lead in the pelvis using a combination of high resolution anatomical MRI sequences and diffusion tensor imaging (DTI). To do so, the patient will undergo a MRI scan (3 Tesla) of the pelvis using sequences including anatomical sequences and diffusion tensor imaging technique for construction of sacral nerve tractography prior to permanent SNS. This will be performed over an hour: first 30 minutes for anatomical sequences and the second 30 minutes for DTI sequencing.
INTRODUCTION: anorectal malformations (ARM) are among the most common congenital anomalies in pediatric surgery. Early detection and management of vestibular fistulas are crucial for optimal outcomes, capitalizing on the pliability of sphincter muscles and the preservation of somatosensory integration. This study aimed to assess the incidence, clinical presentation, and management outcomes of vestibular fistula ARM in a low-income hospital setting.
METHODS: a retrospective audit was conducted on female pediatric patients aged up to 12 years treated for vestibular fistula ARM from January 1, 2011, to June 30, 2016. Data were collected from medical records, and patients were categorized into one of three surgical management groups. Clinical assessments, preoperative procedures, and surgical interventions were meticulously documented.
RESULTS: among 656 neonates, the incidence of vestibular fistula ARM was 8.2%. Patients presented at various ages, with 69.4% being early presenters. Notably, 11.1% of cases presented after 30 weeks of age. Functional fistula, constipation, and bowel obstruction were common presenting symptoms. Associated anomalies were relatively low. The choice of surgical approach varied, with a predominant 3-stage at 68%. Complication development did not significantly differ between surgical groups (p-value 0.083). Immediate postoperative complications were minimal, but complications at definitive anoplasty varied among the surgical groups. Anal strictures and fistula recurrence were noted. At 12 months post-surgery, anal strictures persisted in 9 participants.
CONCLUSION: this study highlights the challenges and outcomes associated with vestibular fistula ARM in a resource-constrained setting. The 3-stage approach, despite its historical preference, demonstrated suboptimal outcomes. A 2-stage procedure appears to offer a balanced alternative, particularly suitable for low-income healthcare systems. Further research and collaborative efforts are essential to refine the management of vestibular fistula ARM and improve patient outcomes.
A coloured solid article having one or more highlighted intagliations (i.e. any stamped or engraved figure, mark, etc.) is coated with at least one film consisting of (a) an optically anisotropic substance (I) of min. refractive index not over 2, and (b) a film-coating agent (II). The article is esp. a tablet or bolus, or a piece of sugar confectionery. The article may be treated, before application of the (I)-contg. layer, with a film contg. a colouring agent, e.g. iron oxides, carmine, natural dyes, water-soluble dyes or their Al lakes, opt. together with an opaque white pigment, esp. TiO2. Claimed (II) are cellulose ether; cellulose acetate phthalate; hydroxypropyl methylcellulose phthalate; polyvinyl acetate (or its phthalate); cellulose acetate; shellac and/or an acrylic resin. - The coating process used is cheaper and quicker than printing and the intagliations are given a colour different from that of the remainder of the tablet etc..
HGT1b bladder cancer patients will undergo a 2nd TUR after BCG induction. If negative, continue with maintenance BCG followed by conventional follow-up (cystoscopy and cytology every 6months).
The PRO2 study is being conducted by palleos healthcare GmbH, the sponsor of the study, with the participation of an expected 585 patients at 40 study sites in Germany and 10 study sites in the German-speaking part of Switzerland with the aim of investigating the medical benefit of the smartphone application medidux™ (app) with regard to the occurrence of side effects in breast cancer therapy. Furthermore, the potential impact on the application of the chemotherapy or antibody-drug conjugate, respectively, the number of unplanned doctor visits, as well as hospitalizations and how often the app is used will be investigated.

The app was developed by mobile Health AG and is intended to accompany therapy. It is an approved CE-marked medical device that will be used in the study within the intended purpose. Study participants can use the app to document symptoms and well-being, as well as vital signs (e.g., blood pressure), and complete a test that can be used to assess mental performance. The entries can be viewed by the study physician through the medidux™ web application. The study participants can refer to the entries during the treatment visit to explain the course of therapy and perceived symptoms. As part of the study, use of the app will be compared to the normal treatment routine (without the app). A randomization process will determine whether study participants receive the app. The probability of receiving the app is 50%. If study participants receive the app, it can be used after installation on the personal smartphone. The approximately 12- to a maximum of 16-week observation period begins with the regular breast cancer therapy. The specific treatment of the breast cancer is not interfered with during the study, i.e. the administration of the therapy itself is carried out in the same way as it would be without the app.
The study objectives are to compare the immediate effect of intermittent vs. continuous walking on clinical and mechanistic pain profiles in persons with knee osteoarthritis (OA). The investigators hypothesize that continuous walking will result in greater increases in clinical pain and mechanistic pain sensitivity than intermittent walking. Physical activity (PA) has been recommended as the first-line management strategy for people with chronic knee pain. Walking is an accessible, low-cost, joint-friendly form of PA and is widely advocated for older adults with knee complaints. However, movement-evoked pain is a commonly cited barrier for PA engagement. On one hand, a bout of PA may produce short-term analgesia and reduce pain. On the other hand, excessive or prolonged PA may exacerbate symptoms and lead to avoidance/fear of subsequent PA. Besides the total PA volume, how it is accumulated could also impact joint health. It is biomechanically plausible that shorter and frequent activities are more beneficial to articular tissues than longer and infrequent activities. Compared to intermittent loading, prolonged continuous loading had a detrimental effect on the biomechanical functions of articular cartilage in a bovine model. Findings of this study will provide insight on the relations between patterns of PA and pain profiles.
Cases of serious skin reactions, sometimes fatal, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) [see Warnings and Precautions (5.7)], have been reported with AUBAGIO. Fatal outcomes were reported in one case of TEN and one case of DRESS.

Inform patients of the signs and symptoms that may signal a serious skin reaction. Instruct patients to discontinue AUBAGIO and seek immediate medical care should these signs and symptoms occur. Unless the reaction is clearly not drug related, discontinue AUBAGIO and begin an accelerated elimination procedure immediately [see Warnings and Precautions (5.3)]. In such cases, patients should not be re-exposed to teriflunomide [see Contraindications (4)].
FIELD: medicine.SUBSTANCE: group of inventions relates to the field of medicine and is intended for production and application in the food, perfume and pharmaceutical industry of the composition possessing antimicrobial and antitoxic action. Composition with supramolecular structure of colloidal mixture of complex compounds of nanostructured silver particles includes active metals in form of binary mixture of colloidal solution of nanostructured silver particles with particle size of 2–100 nm and colloidal solution of silver cations; silver cation restorer selected from citric acid and ascorbic acid; stabilizer of binary mixture of colloidal solution of nanostructured silver particles and silver cations in aqueous dispersion in form of polyvinyl alcohol; distilled water or deionized water. Colloidal solution of silver cations contains a hydrosol of silver cations in an aqueous or aqueous organic solution. Composition includes complex compounds of an emulsifier in form of sodium dioctyl sulphosuccinate surfactants, a dispersing agent in form of a heterocyclic compound of polyvinylpyrrolidone, a thickener in form of glycerol, complexing biologically active substances in the form of mycelium "OVODORIN" mycolic extract and a carrier of a colloidal mixture of propylene glycol complex compounds. Components are used in claimed amounts. Method of producing said composition is also provided.EFFECT: use of the group of inventions enables to obtain a composition with a supramolecular structure synthesized based on complex compounds of nanostructured particles of silver and/or hydrosol of silver cations with formation of stabilized synthesized structures, wherein the composition has antimicrobial and antitoxic action.2 cl, 6 tbl, 7 ex
Participants attend two sessions. They complete movement assessments and questionnaires about physical activity. During the first session they bicycle in a semi-immersive (projected on a screen) and an immersive (with googles) virtual environment. After each bout they completed a questionnaire about the experience. In the second session they bicycle four times with and without a virtual environment using both a continous and interval mode. Their oxygen consumption is measured during cycling. They complete questionnaires after each exercise bout.
Vascular endothelial cells are equipped with numerous specialized granules called Weibel-Palade bodies (WPBs). They contain a cocktail of proteins that can be rapidly secreted (3-5 min) into the vascular lumen after an appropriate stimulus such as thrombin. These proteins are ready without synthesis. Von Willebrand factor (VWF) and P-selectin are the main constituents of WPBs. Upon stimulation, release of ultralarge VWF multimers occurs and assembles into VWF strings on the apical side of endothelium. The VWF A1 domain becomes exposed in a shear-dependent manner recruiting and activating platelets. VWF is able to recruit leukocytes via direct leukocyte binding or via the activated platelets promoting NETosis. Ultralarge VWF strings are ultimately cleaved into smaller pieces by the protease ADAMTS-13 preventing excessive platelet adhesion. Under carefully performed flowing conditions and adequate dose of Shiga toxins, the toxin induces the release of ultralarge VWF multimers from cultured endothelial cells. This basic information allows insight into the pathogenesis of thrombotic thrombocytopenic purpura (TTP) and of STEC-HUS in the diarrhea phase. In TTP, ADAMTS-13 activity is deficient and systemic aggregation of platelets will occur after a second trigger. In STEC-HUS, stimulated release of WPB components in the diarrhea phase of the disease can be presumed to be the first hit in the damage of Gb3 positive endothelial cells.
Healthy participants received insulin glargine (60 mU/m\^2/min) administered IV over 8 hours in Period 4. All periods were separated by a minimum 6-day washout period.
No attempt will be made on individuals in the control group during the research process. After the research process is over; After the training booklet, Mp3 player loaded with directed imagery recording and exercise materials are delivered, guided imagery application based on the Health Promotion Model will be supported by training and counseling.
Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2, 1.0 mg on Day 3, 1.5 mg on Day 4, and 2.0 mg on Days 5-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 2.0 or 3.0 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 2.0, 3.0, or 4.5 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
The present invention refers to monocytes and macrophages for use in the treatment of intravertebral disc (IVD) herniation. Furthermore, the macrophage cell phenotype which is most effective for use in a phagocytosis immunotherapy is herein disclosed. Thus, the present invention provides compositions comprising such macrophage phenotypes and a method for differentiation, polarization, and purification of the most effective macrophage phenotype, as well as its preferred form of administration. Another aspect of the present invention refers to the compositions employed in the said polarization of the most effective macrophage phenotype. Yet another aspect of the present invention refers to the compositions employed in the purification of the most effective macrophage phenotype through negative selection. The uses, compositions and methods of the present invention can be advantageously employed in a cell-based therapy primarily for use in the treatment of intervertebral disc (IVD) herniation, as well as for other clinical conditions improved by the regression of regeneration-adverse reactive tissues, such as wound and surgery- related scar tissue, fibrosis and necrosis; the said clinical condition being selected from the list further consisting of myocardial infraction, endometriosis, pulmonary asthma, hepatic cirrhosis, spinal cord injury and cartilage injury.
The process for extracting SOD comprises the following steps: washing earthworm, purifying, preparing SOD mother liquor from the osmotic solution, rough filtering, centrifuging to obtain supernatant, ultrafiltering, concentrating by reverse osmosis, freeze drying, packaging and warehousing. The SOD wine comprises: red date 4%, hawthorn 2%, ganoderma lucidum 0.4%, garlic 0.2%, first-level jasmine tea 0.4%, ethanol (V/V) 23-28%, and SOD enzyme activity more than or equal to 80 units/ml. The SOD beverage comprises: 2.5 g/l natural SOD dry powder, a trace amount of stevioside, citric acid and spices are added into leaching liquor of the hawthorn, the red dates and the tea. The SOD enzyme activity is more than or equal to 50 units/ml. The method has the following outstanding effects: wide raw material selection, simple process, high SOD extraction rate and low cost. The SOD health-care food has unique flavor and unique health-care effect.
FIELD: veterinary immunology. SUBSTANCE: antigen is prepared by glanders pathogen culturing on nutrient medium from Kursk biofactory for 10-14 days. Grown culture is concentrated and purified by diafiltration on membranes (pore size is 0.1-0.22 mcm). Then cells are stained with 1% solution of an organic dye amount of that is assayed by titration. Obtained antigen can be used in veterinary science for express-diagnosis of glanders by detection of antiglanders antibodies in blood serum of infected animals. EFFECT: improved method of preparing, enhanced effectiveness of diagnosis. 2 cl, 1 tbl
A medication dispensing system provides convenient patient access to health care provider prescribed medications without traveling to an off-site retail pharmacy. A physician input system such as a PDA receives prescription information from the health care provider and communicates the prescription information to at least a prescription computer. The prescription computer performs at least one transaction with at least one insurance company system and subsequently determines the cash price owed by the patient for the medication. The prescription computer also causes a prescription label printer to print a prescription label to be affixed to the vial containing the filled prescription. A technician fills the prescription based on the prescription information and completes a transaction with the patient for the cash price owed on the prescription. An order computer uses the prescription information to order medications to replenish the medications prescribed from a medication wholesaler, and a report printer prints a log of the activity of the medication dispensing system.
Psychological treatments of MS-related fatigue mostly depend on energy conservation programs. We argue that the evidence for energy conservation training is weak - in contrast to some reviews on this topic. The reasons for our concerns are the use of informed passive control groups allowing negative placebo effects, the lack of predefined primary outcome parameter, statistically rather than clinically significant effects, and the use of insensitive fatigue questionnaires. We propose to base psychological interventions not on a view of fatigue as a constant loss of mental energy but as a subjective representation ("feeling") of an inflammatory state, which draws away attentional capacity. This conceptualization allows to develop a three-step treatment approach: Getting short-term control on fatigue, extinction to reduce fatigue-related avoidance behavior, and a systematic increase of activities by pacing. Our proposal depends on the techniques, that can interrupt ongoing feelings of fatigue and can serve as a basis for extinction. We propose that Progressive Muscle Relaxation might be such a technique. The advantage of our model is that it shares similarities with well-established treatments for phobias and chronic pain and we discuss the shared set of assumptions. Hopefully, this will help to improve the treatment of fatigue in future.
Subjects randomized to receive placebo will take placebo twice a day (Exception: children in the lowest weight group ( ≥ 15 - \< 20 kg) will start once a day for Days1-13). The pattern of dose escalation will be the same as the active compound. After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
A cleanser is provided comprising a glycerin based mixture which may have been aerated. The aerated mixture may be combined with a selected fragrance and a selected colorant. The selected fragrance and colorant may correspond to a food product such as a vegetable, fruit, ice cream or the like. Moreover, first and second aerated mixtures may be extruded out of a funnel simultaneously into a rotating container to impart a swirl configuration on the mixtures filling the container. The aerated cleanser may be combined with real food products such as vegetable and fruits. Lastly, the aerated cleanser of the present invention may be formed into a scooped ice cream shape by scooping the same with an ice cream scoop.